Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6825131 | 0.88 | MAPT (0.51) | LMNATSHRMAPTMAPK1HTT | |
| SCHEMBL6828203 | 0.87 | MAPT (0.60) | LMNATSHRMAPTMAPK1HTT | |
| SCHEMBL6830213 | 0.87 | KDM4E (0.59) | LMNAMAPTMAPK1HTTRAB9A | |
| SCHEMBL6825222 | 0.85 | SETD7 (0.52) | LMNATSHRMAPTMAPK1HTT | |
| SCHEMBL6825567 | 0.84 | MAPT (0.49) | LMNATSHRMAPTMAPK1HTT | |
| SCHEMBL6828198 | 0.83 | MAPT (0.60) | LMNAMAPTMAPK1HTTRAB9A | |
| SCHEMBL6828204 | 0.82 | SMN1; SMN2 (0.70) | LMNATSHRMAPTMAPK1HTT | |
| SCHEMBL6825586 | 0.82 | MAPT (0.58) | LMNATSHRMAPTMAPK1HTT | |
| SCHEMBL6825618 | 0.81 | MAPT (0.60) | LMNATSHRMAPTMAPK1HTT | |
| SCHEMBL6828188 | 0.80 | MAPT (0.55) | LMNATSHRMAPTMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138269-A1 | Substituted pyrroles as kinase inhibitors | SUGEN, INC. | 2004-07-15 | — | — | US | claimed |
| US-20040138269-A1 | Substituted pyrroles as kinase inhibitors | SUGEN, INC. | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138269-A1 | Substituted pyrroles as kinase inhibitors | PHKG1, PHKG2, MAP3K20 | LMNA 2490/4885TSHR 3396/4885MAPT 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.